Appointment Completes Executive Readiness for Registrational Phase ALS Study Launch , /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D.
as its new EVP and COO, effective as of . Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy.
His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for in 2022. Dr. Hartounian founded and managed the growth of four biotechnology companies.
He has a track record of achieving aggressive goals at large pharmaceutical, contract development and manufacturing organizations, as well as at start-up biotechnology companies. In his new role, Dr. Hartounian will oversee all operational aspects of BrainStorm Cell Therapeutics, including CMC and commercialization.
He has the right skillset to enhance the company's operational efficiency and the strategic vision to support the commercial readiness of its therapeutic platforms including NurOwn® for amyotrophic lateral sclerosis (ALS). , President and CEO of Brainstorm Cell Therapeutics, commented, "We are pleased to welcome Dr. Hartounian to our team.
His broad experience and proven track record will be invaluable as we continue to advance NurOwn, our in.
